Screener
Arcutis Biotherapeutics, Inc. ARQT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income (loss) | $3,714 | $(40,946) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Stock-based compensation expense | 23,452 | 20,267 |
| Amortization of intangible assets | 1,125 | 3,542 |
| Non-cash interest expense | 941 | 846 |
| Net accretion on marketable securities | (405) | (1,554) |
| Other non-cash items, net | 491 | 348 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s stock-based comp?
- Arcutis Biotherapeutics, Inc. (ARQT) reported stock-based comp of $12.76M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s stock-based comp changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s stock-based comp increased by 21.7% year-over-year, from $10.49M to $12.76M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s stock-based comp has grown at a 14.0% compound annual growth rate (CAGR), from $23.89M to $40.36M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Arcutis Biotherapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude